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Abstract
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis. It is a persistent global health problem
with a high mortality rate. Currently, TB is controlled by administering the Bacillus Calmette-Guerin (BCG) vaccine, but
the effectiveness of its protection varies among individuals in a population. The pe/ppe gene family comprises a typical
group of genes that play a role in avoiding the host immune response and inducing persistent TB infection. Based on in
silico analysis, the pe11 gene has estimated immunogenicity and potential as a TB seed vaccine candidate. The pe11 gene
from an Indonesian isolate of an M. tuberculosis Beijing strain was amplified by polymerase chain reaction (PCR) and
inserted into the mammalian expression vector pcDNA3.1. The recombinant vector pcDNA3.1-pe11 was used to transform
Top10 competent Escherichia coli. Clones from the transformation were subjected to colony PCR to confirm the direction
of the insert. Sequencing was performed to confirm the correctness of the insert sequence. In this study, the pe11 gene was
successfully cloned into the pcDNA3.1 vector in the correct direction to assure PE11 expression. No mutations were found
in the pe11 gene insert, compared with the M. tuberculosis H37Rv sequence as the standard. A pcDNA3.1 vector containing the pe11 gene derived from an M. tuberculosis Beijing strain was successfully constructed.
Keywords: Tuberculosis, M. tuberculosis, pcDNA3.1, pe11

adults and immunocompromised or HIV-positive individuals [5, 7–8]. On the other hand, TB often occurs as
a co-infection with HIV [4–5]. The BCG vaccine has
varying degrees of efficacy against pulmonary TB infection, especially in developing countries [1, 6] and
for populations with TB infection by M. tuberculosis Beijing strains [9]. Thus, a better study of new TB
vaccine candidates is needed [8, 10].

Introduction
Tuberculosis (TB), caused by Mycobacterium tuberculosis, is transmitted through air that has been contaminated with the bacterium. TB infection is a persistent
global health problem, especially in developing countries such as India, Indonesia, Nigeria, Pakistan, and
South Africa [1]. The World Health Organization reports that there are 10.4 million new TB cases, 1.8
million of them fatal, worldwide, but only 6.1 million
cases are detected and officially reported [1–3]. The
prevalence of tuberculosis infection places it among
the 10 most common causes of death in the world. In
Indonesia, it is estimated that one million new TB cases occur each year, and Indonesia was among the five
countries with the highest number of TB cases worldwide in 2015–2017 [3–4].

DNA vaccines are a safer form of the vaccine to give
for various groups of people [8, 11–12] and can stimulate the host's humoral and cellular immune responses
to various diseases, especially infectious diseases [13–
15]. This type of vaccine consists of vectors that are
inserted with specific antigen-encoding genes from
specific microbes [8, 15]. The vector used must express the inserted gene, which later on can induce an
adaptive and cellular immune response, for example,
the T-cell response that is needed to make an effective
TB vaccine [12, 15]. The vector’s selection is adjusted
to the target cell for the expression of the antigencoding gene [8, 15]. The pcDNA3.1 vector is a plasmid commonly used in recombinant protein expression
systems in mammalian cells. Moreover, the pcDNA3.1

Vaccination is one of the most effective interventions
for suppressing TB cases, along with anti-tuberculosis
drug treatment [5]. The anti-TB vaccine currently in
use is Bacillus Calmette-Guerin (BCG), a live attenuated vaccine derived from Mycobacterium bovis [5–7].
However, the BCG vaccine is less able to protect
35
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plasmid is widely used for cancer gene therapy16 and
the development of recombinant DNA-based vaccines
for infectious diseases.17 In constructing a DNA vaccine, specific antigens are needed that can induce an
immune response [8, 15, 18].
The pe/ppe gene family is one of the pathogenic features
of Mycobacterium, comprising 8–10% of the whole
genome of M. tuberculosis.19 The members and roles of
the pe/ppe gene family have not yet been fully elucidated,
hence the pe/ppe family is predicted to contribute to
the level of M. tuberculosis virulence [20–21]. One
gene member of this family, pe11, is known to have a
major role in directing the occurrence of infection and is
considered as one of the factors that allows M. tuberculosis
to evade the host immune system, especially macrophages
[22–24]. In silico analysis shows that PE11 can induce
the adaptive host immune response, which leads to its
other potential function as a biomarker in extrapulmonary
TB in children [25].
Research on the pe11 gene, especially as a vaccine
candidate, is scarce, and no research on pe11 has been
found in Indonesia. The role of PE11 in inducing cytokines such as IL-4, IL-10, IL-1β, and TNF-α has been
carried out to observe the role of the pe11 gene in Mycobacterium smegmatis infection in test animals. In
this study, PE11 induced IL-4, IL-10, and TNF-α as a
cellular immune response [23]. In general, genes in the
pe/ppe family can be developed as candidates for a
tuberculosis vaccine; moreover, the protein profile of
PE/PPE has the opportunity to be used as a diagnostic
tool for M. tuberculosis infection26. Based on this
fact, there is still an opportunity to conduct research on
pe11 in the framework of protective efficacy against
M. tuberculosis infection.
This study aims to clone the pe11 gene from an Indonesian isolate of an M. tuberculosis Beijing strain into
the pcDNA3.1 vector, which can be used as an expression vector in a mammalian system to produce recombinant PE11 protein. The recombinant plasmid can be
subsequently tested in an animal model to analyze its
ability to induce immunity and be considered for use
as a TB vaccine candidate that can be produced in Indonesia.

Material and Methods
Strains. M. tuberculosis Beijing and Escherichia coli
Top10 strains are stock cultures of the Microbiology
Department, Faculty of Medicine, Universitas Indonesia.
DNA Extraction. Genome isolation was carried out
using the boiling technique at 95 °C for 30 minutes,
followed by centrifugation at 8000 rpm for 10 minutes.
The supernatant consisted of genomic DNA, which was
removed to a fresh tube and stored at −30 °C until use.
Makara J. Sci.

Epitope Analysis. Epitope analysis of pe11 gene expression was conducted by using the Immune Epitope
Database (iedb.org). Analyses were performed by submitting the PE11 amino acid sequences. We performed
epitope prediction on T cells, especially on the MHC II
binding site, and on B cells. The methods of epitope
prediction included a consensus approach that combined
NN-align, SMM-align, and combinatorial library methods.
Amplification of the pe11 gene. Amplification of the
pe11 gene was performed using the polymerase chain
reaction (PCR) technique with a specific primer that
annealed to the target region of the gene. The BamHI
restriction site was added to the forward primer. Meanwhile, the EcoRI restriction site was added to the reverse
region. The sequences of the forward and revers primers
were 5′-CGCGGATCCATC.TTTTGTCACCACACGGC3′ and 5′-CGCGAATTCCT GCCCGCGCG-3′, respectively. The forward primer contained the Kozak sequence. We did not include the complete primer sequences for patent purposes. The PCR reaction consisted of 10 pmol forward and reverse primers, 52 μL nuclease-free water, 25 mM MgSO4, 10 μL dNTP mix, 10
μL DMSO, 10 μL 10X reaction buffer, 2 µL SMO-Hifi
DNA polymerase [Smobio], and 10 µL of the M. tuberculosis genome to a final reaction volume of 100 µL.
The PCR program consisted of an initial denaturation
for 2 minutes at 94 °C, followed by 30 cycles of 15 seconds at 94 °C, annealing for 30 seconds at 65 °C, 30
seconds at 68 °C, and a cycle at 68 °C for 1 minute. The
PCR product size was confirmed through gel electrophoresis, and the fragment was purified using the
GeneJET PCR Purification Kit [Thermo Scientific].
Preparation of the pcDNA3.1 Vector. The pcDNA3.1
[Thermo Scientific] vector is the stock of the Virology
and Molecular Laboratory Microbiology Department,
Faculty of Medicine, Universitas Indonesia. Plasmids
were propagated in E. coli strain DH5α on Luria Bertani
broth medium containing 100 μg/ml ampicillin and then
isolated by using the GeneJET Plasmid Miniprep Kit
[Thermo Scientific]. The results of plasmid isolation
were observed by 8% agarose gel electrophoresis.
Cloning of pe11 into the pcDNA3.1 Vector. The PCR
product of pe11 and the pcDNA3.1 plasmid were digested with the restriction enzymes BamHI [Thermo
Scientific] and EcoRI [BioLabs] in an incubator for two
hours at 37 °C, followed by ethanol precipitation with
addition of 1 M NaOAC and absolute ethanol. The solution mix was then centrifuged at 13,500 rpm and 4 °C
for 15 minutes. The supernatant was discarded, and 70%
ethanol was added to the pellet. Centrifugation was performed again for 5 minutes, then the supernatant was
removed. The DNA pellet was dried in a DNA dryer for
10 minutes, and finally, 10 μL nuclease-free water was
added to the dissolved DNA pellet. The result of this
March 2021  Vol. 25  No. 1
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step was used for ligation. The ligation reaction consisted of pcDNA3.1 plasmid, the pe11 DNA fragment, 10
µL T4 DNA ligase buffer [Fermentas], 1 µL T4 Ligase
enzyme [Thermo Scientific], and nuclease-free water to
a total reaction volume of 30 µL. Furthermore, the reaction mix was incubated at 16 °C overnight and used for
recombinant plasmid transformation into E. coli Top10
competent bacteria.
Transformation of Recombinant Plasmid. The recombinant plasmid was used to transform E. coli Top10
competent bacteria by using the CaCl2 method, the details of which can be found elsewhere. Bacterial transformants were then spread on LB plate medium containing 100 µg/mL ampicillin, followed by overnight incubation at 37 °C. Colony PCR was performed to obtain
bacteria that had been successfully transformed with
pCNA3.1-pe11 recombinant plasmid. Positive colonies
were then re-cultured into LB broth medium containing
ampicillin 100 µg/ml in a shaking incubator at 37 °C,
followed by plasmid isolation. Furthermore, sequencing
analysis was conducted to identify the existence of mutations.

Results
Epitope Analysis. The PE11 epitope analysis results
showed the regions that could be recognized by the
Human Leukocyte Antigen (HLA) or Major
Histocompatibility Complex II (MHC II). This complex
is on the surface of Antigen Presenting Cells, such as
macrophages, B cells, and dendritic cells. The data
obtained show that HLA can recognize PE11, including
HLA-DR, HLA-DP, and HLA-DQ. The analysis was
continued to predict some epitopes for antibody
recognition. We used predictive computing using the
Bepipred Linear Epitope Prediction method, Sequential
B-cell Epitope Predictors, which are sequence-based Bcell epitope predictions using conformational epitopes.
The BepiPred-2.0 server predicts B-cell epitopes from a
protein sequence, using a Random Forest algorithm
trained on epitopes and non-epitope amino acids
determined from crystal structures. The results indicate
that at least five possible epitopes will be recognized by
human B cells (Figure 1). Yellow curves above the
threshold line (0.350) indicate the possibility of epitopes
recognized by B cells. This suggested the potential of
PE11 to induce the host's adaptive immune response.
Amplification of the pe11 gene. Amplification of the
pe11 gene from the Beijing strain M. tuberculosis
genome was successfully carried out using the PCR
method. As shown in Figure 2, we confirmed the
presence of a 324-bp band corresponding to the length
of the target pe11 gene on 1.5% agarose gel
electrophoresis. These results indicate that the primers
designed and the PCR conditions are suitable to produce
the expected PCR products.
Makara J. Sci.

a.
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Epitope region

b. Predicted peptides*
No
Start
End
Peptide
1
6
14
TRPDSIGET
2
16
16
A
3
26
34
SAHDDGVTP
4
39
44
VESPAH
5
81
83
QTS

Length
9
1
9
6
3

*Rewritten from Bepipred Linear Epitope Prediction result
Figure 1. In silico Epitope Prediction using the Immune
Epitope Database (iedb.org). a) Prediction of
Epitope for HLA, Yellow Area Shows the Region of PE11 that can be recognized as an
Epitope for HLA. b) Analysis of Epitope Sequences for B cells.

Figure 2. . PCR Product of the pe11 gene (324 bp) from
M. tuberculosis Beijing Strain Separated on
1.5% Agarose Gel Electrophoresis. Lane M: 1
kb DNA Ladder; Lane 1: PCR Product of the
pe11 Gene-Coding Region. Black Arrow
Showed a Band Correlates to the Length of
pe11. bp = base pair..
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recombinant plasmid. Some colonies produced a DNA
band at 324 bp, showing that the pe11 gene had been
successfully inserted into the plasmid vector (Figure
3b). We illustrate the cloning of the pe11 gene into the
plasmid vector pCDNA3.1 in Figure 4. In our construct,
the pe11 gene was inserted downstream of the CMV
promoter, with a stop codon added to the downstream
region of the pe11 gene; in theory, only PE11 protein
expression would occur. This construct is expected to
express PE11 protein in vivo and stimulate an immune
response in test animals.
a

b
Figure 3. a) Pe11 gene and pcDNA3.1 Vector Digested
with BamHI and EcoRI Separated on 1.5%
Agarose Gel Electrophoresis. M: 1 kb DNA
Ladder. Lane 1: pe11 gene; and Lane 2:
pcDNA3.1 Vector after Digestion with Restriction Enzymes; Lane 3: pcDNA3.1 Undigested. Gray Arrow Shows a Band Correlating to the Length of pCDNA3.1 after Digestion.
Black Arrow Shows a Band Correlating to the
Length of pe11. b) Colony PCR with Primers
Specific to pe11. M: 1 kb DNA Ladder; Lane 1–
5: Colony PCR from E. coli Transformation
Results. Black Arrow shows a Band Correlating to the Length of pe11. bp = Base Pair

Ligation and Transformation of Recombinant
Plasmid Into Bacteria. PCR products of pe11 after
isolation and purification of pcDNA3.1 were subjected
to digestion using the restriction enzymes BamHI and
EcoRI. We confirmed the digestion result on 1.5%
agarose gels, as can be seen in Figure 3a. Although the
results of restriction enzyme digestion of pe11 were not
visible, the success of the digestion could be observed in
the plasmid pcDNA3.1, where there was a single linear
band compared with the uncut plasmid. Digestion by
restriction enzymes was followed by ligation of the
pe11 gene into the pCDNA3.1 vector using T4 DNA
ligase. After overnight incubation, the ligation product
was used to transform E. coli Top10 bacteria, which
were grown on LB agar containing ampicillin as
selective media. Then, colony PCR was performed with
specific primers to detect the pe11 gene insert in the
Makara J. Sci.

Sequencing analysis of pe11 from pCDNA3.1-pe11
recombinant plasmid. For the purpose of observing
any mutations in the pe11 gene insert, we isolated two
colonies and performed PCR using primers that
annealed to upstream regions of the plasmid and reverse
regions of pe11. The electrophoresis results showed a
band of 484 bp correlated to the expected length of the
amplicon region (figure not shown), indicating that the
direction and location of insertion were correct in the
plasmid vector. Then, we sequenced the amplicon of the
pe11 DNA insert and analyzed the thread of sequence.
Analysis of the sequencing results showed that no
mutations had occurred in the DNA insert, and the
sequence was 100% similar to that of pe11 from M.
Tuberculosis H37Rv as standard sequences (Figure 5).

Figure 4. Construction of Recombinant pcDNA3.1 Plasmid Containing pe11 DNA

March 2021  Vol. 25  No. 1
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Figure 5. Sequencing Analysis of the pe11 Gene from the pcDNA3.1-pe11 Recombinant Plasmid. pe11 H37Rv = pe11 Sequence from M. tuberculosis H37Rv from http://genolist.pasteur.fr/TubercuList/; pe11 Beijing = Sequencing Result of pe11 from pCDNA3.1-pe11 Recombinant Plasmid

Discussion
Studies on pe11 require additional exploration,
especially to discuss the potential of pe11 as a DNA
vaccine candidate to prevent TB infection and
determine the immunogenic level of pe11 to trigger the
host's adaptive immune response. We attempted to
analyze an epitope of the pe11 protein, which has a
molecular weight of 10.8 kDa with a total of 100 amino
acids by using the Immune Epitope Database (iedb.org).
Analysis using this database is considered quite
representative, and in vitro results were concordant with
in silico analysis in our experience with an RpfD protein
experiment (unpublished data). In this case, the results
of in silico analysis indicated that the pe11 protein has
an epitope to induce humoral and cellular immune
responses in which there are recognition epitopes for
HLA and B cells. As we know, the HLA will present
Makara J. Sci.

antigens to CD4+ helper T cells, which can then activate
T cells, and in a certain mechanism, pathways can also
stimulate B cells to produce antibodies that are specific
to these antigens [27−28].
To study the potential of pe11 as a seed vaccine
candidate, we constructed a plasmid recombinant of
pe11 into the pCDNA3.1 plasmid. We amplified pe11
from an Indonesian isolate of an M. Tuberculosis
Beijing strain using PCR. The selection of Beijing
strains from Indonesian isolates was based on several
studies stating that most of the M. tuberculosis isolates
in Indonesia and some countries in Southeast Asia are
of the Beijing strain [29−30]. They also refer to the
induction of host immune responses, clinical features,
epidemiology, and pathogenic characteristics that
determine the manifestations of infection that occur.
March 2021  Vol. 25  No. 1
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Various strains of M. tuberculosis determine this [9, 29,
31−32]. Furthermore, BCG vaccine administration in
populations with TB infection by Beijing strains is not
effective for prevention of TB infection by the strains
other than Beijing [9]. Thus, the selection of Beijing
strains in this study is expected to produce a TB vaccine
candidate more specific for the pathogenic character of
M. tuberculosis in Indonesia and be an incentive for
independent production in Indonesia.
The selection of a vector in this study was adjusted to
future goals, specifically applying recombinant vectors
with expression systems in mammalian cells to be used
and tested as TB vaccine seeds [13,16, 18,33]. The pcDNA3.1
vector has a cytomegalovirus (CMV) promoter. The CMV
promoter is one of the strong expression promoters
derived from human cytomegalovirus. This promoter can
drive the expression of exogenous genes in mammalian
cells; therefore, transfection with this vector is the
preferred method for expressing target genes in
mammalian cells [33−34]. In the region downstream of
the CMV promoter where the pe11 gene was inserted.
Moreover, pcDNA3.1 has a bovine growth hormone
region, which signals polyadenylation and is a
transcription termination sequence to increase mRNA
stability [33, 35]. The presence of pUC origin is also
useful for selection and for facilitating the replication of
E. coli bacterial cells [33]. Some members of our previous
research team have proven the success of cloning various
genes into pcDNA3.1, including rpfB and rpfD genes,
which shows that this vector can be a good choice for
cloning various genes of M. tuberculosis [36−37].
As mentioned above, the selection of M. tuberculosis
Beijing strains from Indonesia is expected to provide
unique characteristics of the recombinant protein
produced. However, it was beyond our expectations that
there was no difference found to the standard sequence
of M. tuberculosis H37Rv. It might be that the resulting
protein PE11 would have the same structure to that of
other TB strains. This could potentially lead to the same
immune response among M. tuberculosis strain infection.
Moreover, we think this is an advantage that the pe11 will
protect against any infecting strains of M. tuberculosis.
The vaccine produced subsequently can be applied in a
variety of different M. Tuberculosis infection settings.

Conclusion
We succeeded in constructing the pcDNA3.1 vector
encoding pe11 derived from an M. tuberculosis Beijing
strain. However, further research is needed to examine
the expression of pe11 and the response of adaptive
immunity in an animal testing model. This study is a
promising first step toward a TB vaccine candidate produced in Indonesia.
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